DBV Technologies S.A. (DBVT) At $23.44 Forms Bottom; Pier Capital Trimmed Integra Lifesciences Holding (IART) Position

DBV Technologies S.A. (NASDAQ:DBVT) Logo

Pier Capital Llc decreased Integra Lifesciences Holding (IART) stake by 47.5% reported in 2017Q4 SEC filing. Pier Capital Llc sold 53,473 shares as Integra Lifesciences Holding (IART)’s stock rose 10.84%. The Pier Capital Llc holds 59,103 shares with $2.83 million value, down from 112,576 last quarter. Integra Lifesciences Holding now has $4.36 billion valuation. The stock decreased 0.93% or $0.52 during the last trading session, reaching $55.27. About 342,709 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 29.35% since April 16, 2017 and is uptrending. It has outperformed by 17.80% the S&P500.

DBV Technologies S.A. (DBVT) formed multiple bottom with $21.33 target or 9.00% below today’s $23.44 share price. DBV Technologies S.A. (DBVT) has $1.40 billion valuation. The stock decreased 2.46% or $0.59 during the last trading session, reaching $23.44. About 104,199 shares traded. DBV Technologies S.A. (NASDAQ:DBVT) has declined 34.29% since April 16, 2017 and is downtrending. It has underperformed by 45.84% the S&P500.

Among 16 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 8 Hold. Therefore 50% are positive. Integra Lifesciences Holdings Corp. had 39 analyst reports since July 29, 2015 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Monday, August 3 report. The firm earned “Hold” rating on Friday, September 1 by RBC Capital Markets. The company was maintained on Thursday, July 27 by Raymond James. The company was maintained on Thursday, November 9 by RBC Capital Markets. As per Friday, June 23, the company rating was maintained by Oppenheimer. The firm earned “Buy” rating on Monday, December 12 by UBS. As per Tuesday, January 2, the company rating was downgraded by Raymond James. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Equal Weight” rating given on Friday, July 29 by Barclays Capital. The rating was downgraded by Zacks to “Hold” on Monday, August 24. J.P. Morgan downgraded it to “Hold” rating and $44.0 target in Friday, October 27 report.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.31, from 1.29 in 2017Q3. It is negative, as 20 investors sold IART shares while 70 reduced holdings. 23 funds opened positions while 65 raised stakes. 70.22 million shares or 2.95% more from 68.21 million shares in 2017Q3 were reported. Us Bancorp De has 27,764 shares. First Tru Advsr LP holds 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 18,879 shares. Guggenheim Cap Ltd Com owns 10,828 shares. State Of Tennessee Treasury Department has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 44,533 are owned by Teachers Retirement Of The State Of Kentucky. Champlain Invest Ptnrs reported 4.65 million shares stake. Johnson Financial Group reported 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Morgan Stanley owns 160,654 shares. Massachusetts-based Wellington Mgmt Grp Llp has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). The Massachusetts-based Ngam Advsr Ltd Partnership has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). D E Shaw & Co Inc owns 135,051 shares or 0.01% of their US portfolio. Millennium Mngmt Ltd Liability Company has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Northwest Inv Counselors Ltd Limited Liability Company reported 7,730 shares. Whittier owns 3,344 shares. 2,305 are held by Fortaleza Asset.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on April, 25. They expect $0.49 EPS, up 25.64% or $0.10 from last year’s $0.39 per share. IART’s profit will be $38.69 million for 28.20 P/E if the $0.49 EPS becomes a reality. After $0.64 actual EPS reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts -23.44% negative EPS growth.

Pier Capital Llc increased Fcb Financial Holdings Inc (NYSE:FCB) stake by 35,467 shares to 140,047 valued at $7.11M in 2017Q4. It also upped Ollies Bargain Outlet Holdings stake by 22,154 shares and now owns 140,922 shares. Aerojet Rocketdyne Holdings In was raised too.

Among 11 analysts covering DBV Technologies (NASDAQ:DBVT), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. DBV Technologies has $72 highest and $25.0 lowest target. $40.90’s average target is 74.49% above currents $23.44 stock price. DBV Technologies had 23 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Thursday, June 1 by Jefferies. The stock of DBV Technologies S.A. (NASDAQ:DBVT) has “Overweight” rating given on Tuesday, September 15 by Morgan Stanley. Citigroup maintained the stock with “Buy” rating in Monday, October 2 report. The firm has “Buy” rating by H.C. Wainwright given on Thursday, March 15. The company was maintained on Monday, October 23 by Barclays Capital. The rating was maintained by Jefferies with “Buy” on Thursday, August 31. The firm has “Overweight” rating given on Thursday, December 3 by Barclays Capital. Morgan Stanley maintained DBV Technologies S.A. (NASDAQ:DBVT) on Friday, October 6 with “Overweight” rating. The stock has “Hold” rating by Societe Generale on Tuesday, October 31. The firm has “Buy” rating given on Wednesday, March 16 by Citigroup.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart